摘要
目的:探讨骨化三醇联合盐酸吡格列酮对早期糖尿病肾病(DN)患者血脂、肾功能、炎症因子等指标的影响。方法:120例早期DN患者随机均分为对照组、V组、P组和V+P组。对照组患者给予糖尿病饮食、适度运动,重组甘精胰岛素注射液控制血糖等常规治疗;V组患者在对照组治疗的基础上给予骨化三醇胶丸0.25μg,口服,每日1次;P组患者在对照组治疗的基础上给予盐酸吡格列酮胶囊30 mg,口服,每日1次;V+P组患者在对照组治疗的基础上给予骨化三醇胶丸(用法用量同V组)+盐酸吡格列酮胶囊(用法用量同P组)。各组疗程均为3个月。观察各组患者治疗前后血脂[三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)]、肾功能[血肌酐(Scr)、血尿素氮(BUN)、尿白蛋白排泄率(UAER)]、炎症因子[C反应蛋白(CRP)、肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6]水平及不良反应发生情况。结果:治疗前,各组患者血脂、肾功能、炎症因子水平比较,差异均无统计学意义(P>0.05)。治疗后,对照组患者TC、UAER,V组患者TC、LDL、IL-6、Scr、BUN、UAER,P组、V+P组患者TG、TC、LDL、Scr、BUN、UAER、CRP、TNF-α、IL-6均显著低于同组治疗前,V+P组患者TG、TC、LDL、Scr、BUN、UAER、CRP、TNF-α、IL-6及P组患者TG、Scr、CRP均显著低于对照组,而V+P组TG低于P组,差异均有统计学意义(P<0.05);各组患者HDL治疗前后比较,差异均无统计学意义(P>0.05)。各组患者治疗期间均未见明显不良反应发生。结论:在常规治疗的基础上,骨化三醇联合盐酸吡格列酮可显著降低早期DN患者血脂、改善肾功能及炎症状态,且安全性较好。
OBJECTIVE：To explore the effects of calcitriol combined with pioglitazone hydrochloride on the cholesterol,kidney functions and inflammatory cytokines of patients with early-stage diabetic nephropathy（DN）. METHODS：120 patients with early-stage DN were randomly divided into control group,group V,group P and group V＋P. Control group was given diabetic diet,moderate exercise,Recombinant insulin glargine injection to control blood glucose and other conventional treatment;group V was additionally given 0.25 μg Calcitriol soft capsule,orally,qd;group P was additionally given 30 mg Pioglitazone hydrochloride granule,orally,qd;group V＋P was additionally given Calcitriol soft capsule（the same dosage with group V）＋Pioglitazone hydrochloride granule（the same dosage with group P）. The treatment course for all groups was 3 months. serum lipids indexes [triglyceride（TG）,total cholesterol（TC）,high density lipoprotein（HDL）,low density lipoprotein（LDL）],renal function indexes [serum creatinine（Scr）,blood urea nitrogen（BUN）,UAER],inflammatory cytokines [C-reactive protein（CRP）,tumor necrosis factor（TNF）-α,interleukin（IL）-6] before and after treatment,and the incidence of adverse reactions in all groups were observed. RESULTS：After treatment,there were no significant differences in the serum lipids indexes,renal function indexes and inflammatory cytokines among all groups（P〉0.05）. After treatment,TC and UAER in control group,TC,LDL,IL-6,Scr,BUN and UAER in group V,TG,TC,LDL,Scr,BUN,UAER,CRP,TNF-α and IL-6 in group P and group V＋P were significantly lower than before,TG,TC,LDL,Scr,BUN,UAER,CRP,TNF-α and IL-6 in group V＋P,TG,Scr and CRP in group P were significantly lower than control group,TG in group V ＋ P was significantly lower than group P,the differences were statistically significant（P〈0.05）,and there were no significant differences in the HDL among all groups（P〉0.05）. There were no obvious adverse reactions during treatment. CONCLUSIONS：
出处
《中国药房》
CAS
北大核心
2016年第9期1170-1172,共3页
China Pharmacy
基金
武汉市临床医学科研项目(No.WX15D31)
关键词
骨化三醇
盐酸吡格列酮
早期
糖尿病肾病
Calcitriol
Pioglitazone hydrochloride
Early-stage
Diabetic nephropathy
